Literature DB >> 15169628

Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells.

Rong-Guang Shao1, Chun-Xia Cao, Yves Pommier.   

Abstract

AIM: To investigate whether 7-hydroxystaurosporine (UCN-01) affects cell cycle progression in arabinosylcytosine (ara-C) treated human colon carcinoma HT-29 cells.
METHODS: Cytotoxicity, DNA synthesis, cell cycle distribution, protein level, and kinase activity were determined by clonogenic assay, flow cytometry, DNA synthesis assay, immunoblotting, and kinase assays, respectively.
RESULTS: UCN-01 abrogated an S/G2-phase checkpoint in HT-29 cells treated with ara-C. When UCN-01 was added after treatment with ara-C, the rate of recovery of DNA synthesis was enhanced and colony-forming ability diminished. Thus, premature recovery of DNA synthesis was associated with increased cytotoxicity. Measurements of cyclin A and B protein levels, Cdk2 and Cdc2 kinase activities, Cdc25C phosphorylation, and Chk1 kinase activity were consistent with UCN-01-induced abrogation of the S/G2-phase checkpoint in ara-C treated cells.
CONCLUSION: The abrogation of the S/G2 checkpoint may be due to inhibition of Chk1 kinase by UCN-01. The enhanced cytotoxicity produced when UCN-01 was combined with ara-C suggested a rationale for the use of this drug combination for tumors that might be susceptible to cell cycle checkpoint abrogation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15169628

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  8 in total

1.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.

Authors:  H Christian Reinhardt; Aaron S Aslanian; Jacqueline A Lees; Michael B Yaffe
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

2.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

Authors:  Deepa Sampath; Jorge Cortes; Zeev Estrov; Min Du; Zheng Shi; Michael Andreeff; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

3.  Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.

Authors:  Sheena M Aris; Yves Pommier
Journal:  Cancer Res       Date:  2011-12-21       Impact factor: 12.701

4.  Loratadine dysregulates cell cycle progression and enhances the effect of radiation in human tumor cell lines.

Authors:  Benjamin P Soule; Nicole L Simone; William G DeGraff; Rajani Choudhuri; John A Cook; James B Mitchell
Journal:  Radiat Oncol       Date:  2010-02-03       Impact factor: 3.481

Review 5.  Immune Checkpoint in Glioblastoma: Promising and Challenging.

Authors:  Jing Huang; Fangkun Liu; Zhixiong Liu; Hui Tang; Haishan Wu; Qianni Gong; Jindong Chen
Journal:  Front Pharmacol       Date:  2017-05-09       Impact factor: 5.810

6.  Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.

Authors:  Haijun Zhao; Pengcheng Shi; Manman Deng; Zhiwu Jiang; Yin Li; Vinodh Kannappan; Weiguang Wang; Peng Li; Bing Xu
Journal:  Oncotarget       Date:  2016-12-20

7.  Nuclear morphometric analysis (NMA): screening of senescence, apoptosis and nuclear irregularities.

Authors:  Eduardo C Filippi-Chiela; Manuel M Oliveira; Bruno Jurkovski; Sidia Maria Callegari-Jacques; Vinicius Duval da Silva; Guido Lenz
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

8.  A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy.

Authors:  Thu Le Trinh; Guizhi Zhu; Xilin Xiao; William Puszyk; Kwame Sefah; Qunfeng Wu; Weihong Tan; Chen Liu
Journal:  PLoS One       Date:  2015-11-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.